BofA warns Fed risks policy mistake with early rate cuts
Peter Radovich, President and Chief Operating Officer of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company with a market capitalization of $2.18 billion, sold a total of 14,850 shares of the company’s common stock on March 4, 2025. According to InvestingPro data, the stock has recently experienced a 10.49% decline over the past week, though it maintains an impressive 61.5% gain over the last year. The transactions were executed at prices ranging from $45.5711 to $45.74 per share, resulting in a total sale value of approximately $676,928. Following these sales, Radovich holds 12,111 shares of Mirum Pharmaceuticals. InvestingPro analysis indicates the company is currently fairly valued, with analysts maintaining a strong buy consensus and healthy financials, including a solid current ratio of 3.1. Additional insights and 8 more ProTips are available through InvestingPro’s comprehensive research report.
In other recent news, Mirum Pharmaceuticals reported fourth-quarter earnings that did not meet analyst expectations, with an adjusted loss of $1.85 per share compared to the anticipated $0.30 loss per share. However, the company’s revenue for the quarter was $99.41 million, surpassing the consensus estimate of $95.4 million and marking a 55.6% increase from the previous year. Mirum’s LIVMARLI drug net sales reached $64.1 million in the fourth quarter of 2024, contributing to the total 2024 sales of $213.3 million. The company also reported full-year 2024 net product sales of $336.4 million, a significant increase from $178.9 million in 2023.
Looking ahead, Mirum provided guidance for 2025, projecting global net product sales between $420 million and $435 million. In addition, H.C. Wainwright analyst Ed Arce raised the price target for Mirum to $72 and maintained a Buy rating, following the company’s announcement that it is on track to meet its 2025 global net product sales guidance. Mirum is also advancing its Phase 2 VISTAS study of volixibat for primary sclerosing cholangitis, with enrollment completion expected in the second half of 2025. The company ended 2024 with $292.8 million in cash, cash equivalents, and investments, an increase from the previous year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.